Active	Status	Sponsor type	Region	Phase	Filter
9 Active 2 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ogdie-Beatty, Alexis
NCT04535999: Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)	Recruiting	4	40	US	Secukinumab Auto-Injector, Cosentyx	University of Pennsylvania, Novartis	Psoriasis	12/25	12/25
NCT05631457: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)	Not yet recruiting	3	300	US	Guselkumab Prefilled Syringe [Tremfya], Tremfya, Golimumab, Simponi	University of Pennsylvania, Janssen Scientific Affairs, LLC	Psoriatic Arthritis	05/25	05/25
EVOLUTION, NCT05669833: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients	Recruiting	3	150	US	Guselkumab, Tremfya, Golimumab, Simponi	University of Pennsylvania, Janssen Scientific Affairs, LLC	Psoriatic Arthritis	05/26	05/26
NCT03737045: Psoriatic Arthritis and Psoriasis Treatment Decision Aid	Active, not recruiting	N/A	100	US	Decision Aid	University of Pennsylvania, Pfizer	Psoriatic Arthritis, Psoriasis	12/24	12/24